Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.04
$0.06
$0.02
$0.78
$1.71M1.175,210 shs52 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$0.74
-0.2%
$2.41
$0.69
$29.40
$5.05M1.072.54 million shs633,040 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.70
-3.7%
$0.78
$0.65
$7.50
$5.40M0.25123,159 shs76,724 shs
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$3.20
-1.2%
$3.38
$2.20
$5.27
$5M2.3252,563 shs21,332 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%+15.56%-66.67%+20.42%+100.50%
Briacell Therap stock logo
BCTX
Briacell Therap
-0.21%-6.93%-74.61%-81.40%-93.41%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-4.36%-3.83%-6.63%-50.13%-86.70%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-1.20%-11.21%-18.76%+14.53%-25.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
1.4445 of 5 stars
3.52.00.00.00.60.00.6
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
0.699 of 5 stars
0.05.00.00.00.00.80.6
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
0.8777 of 5 stars
0.03.00.00.01.50.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
3.00
Buy$32.004,201.08% Upside
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
0.00
N/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M0.53N/AN/A($2.06) per share-0.02
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A($2.20) per shareN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/A$10.60 per shareN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$2.50M1.97N/AN/A$3.89 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/AN/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$13.90M-$10.60N/AN/AN/A-88.14%-81.21%8/12/2025 (Estimated)
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$3.96M-$2.38N/AN/AN/A-142.10%-57.31%-49.30%8/12/2025 (Estimated)

Latest ADXS, XBIO, BCTX, and KTTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$0.64N/AN/AN/A$0.48 millionN/A
6/13/2025Q3 2025
Briacell Therap stock logo
BCTX
Briacell Therap
-$1.76-$1.64+$0.12-$1.64N/AN/A
5/15/2025Q1 2025
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A-$1.61N/A-$1.61N/AN/A
5/13/2025Q1 2025
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$0.72-$0.59+$0.13-$0.59$0.52 million$0.59 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
3.41
3.41
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A
3.84
3.84
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A
8.20
8.20

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
23.92%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
15.12%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
Briacell Therap stock logo
BCTX
Briacell Therap
5.73%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
2.70%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
14.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2042.63 million42.36 millionNot Optionable
Briacell Therap stock logo
BCTX
Briacell Therap
86.78 million6.39 millionNo Data
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
37.44 million7.24 millionNot Optionable
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
41.54 million1.32 millionNot Optionable

Recent News About These Companies

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.04 0.00 (0.00%)
As of 07/31/2025

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$0.74 0.00 (-0.21%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.74 0.00 (-0.54%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Pasithea Therapeutics stock logo

Pasithea Therapeutics NASDAQ:KTTA

$0.70 -0.03 (-3.71%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.69 -0.01 (-1.03%)
As of 08/1/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Xenetic Biosciences stock logo

Xenetic Biosciences NASDAQ:XBIO

$3.20 -0.04 (-1.20%)
As of 08/1/2025 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.